Bio-Digital Healthcare Platformfor emotion and cognition
Why Emocog
We create technology that helps sustain brain health
Dementia affects about 10% of the senior population and progresses over a decade. The stage of memory decline before dementia is called Mild Cognitive Impairment (MCI) and progresses overhalf a decade. The prevalence rate is about 25%. Emocog develops solutions for each stage of dementia, including Cogthera, a cognitive improving digital therapeutics for MCI.
Research
Technology based on world-class scientific results
The results of 20 years of research was published in 5 leading *SCI-indexed journals on brain disease.
*Science Citation Index (SCI): renowned journals carefully selected based on strict criteria among science and technology journals
01
Kim et al., 2021, Journal of Medical Internet Research
Emocog builds an ecosystem to care for the entire journey from screening, diagnosis and treatment of dementia. To overcome the physical constraints of not being able to care for every patient every day, we propose innovative solutions utilizing digital technology.
*Digital treatments and medical applications(DiGA) are virtual medical products that are available as apps for mobile devices or as browser applications. Cogthera DE can quickly enter the market and receive very high insurance rates through these process.
MemoryPickMobile Cognitive Assessment Service to Screen for Dementia Risk
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROTOTYPE & TEST
DETAILED DESIGN
DATA COLLECTION & ANALYSIS
LAUNCH
Cogthera KRDigital Therapeutics for MCI
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROOF OF CONCEPT
PROTOTYPE & TEST
DETAILED DESIGN
PERFORMANCE TEST
CLINICAL EVALUATION
PRODUCT APPROVAL
LAUNCH
Cogthera DEGerman-optimized Digital Therapeutics for MCI
AlzVoiceMemory and Attention Assessment Service based on Verbal Conversation
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROTOTYPE & TEST
DETAILED DESIGN
DATA COLLECTION & ANALYSIS
LAUNCH
1
Mobile cognitive assessment service to help screen for dementia risk
MemoryPick
MemoryPick is a digital screening tool that helps users detect early signs of cognitive decline. It evaluates memory and executive function, which are the first cognitive areas to decline due to dementia, as well as subjective cognitive decline and depression.
At the end of the test, it shows an instant results report representing the user’s brain health. Based on the results, it recommends memory strategies to help daily life and lifestyle habits to keep the brain healthy.
It is a responsive web-based online test that can be performed on various devices and operating systems through a QR or a URL.
The test takes only about 5 minutes, providing comfortable and easy-to-use content based on simple words and shapes.
Improve the accuracy of the results through large-scale compliance data by accounting for differences in cognitive function based on age, education, gender, etc.
2
Digital Therapeutics(DTx) for delaying cognitive decline in patients with mild cognitive impairment
Cogthera
Cogthera constantly monitors patients’ cognitive functions and provides personalized cognitive training to strengthen the neural networks and increase the *cognitive reserve.
It was designated as an Innovative Medical Device by MFDS and became the first cognitive intervention treatment software for MCI to be designated as an Innovative Medical Device in Korea.
Conversation-based interface using vocal cues, made for the convenience of patients with early cognitive decline.
The difficulty level automatically adjusts based on the patient’s performance.
Designed for daily use under the guidance and prescription of a healthcare professional.
DiGA Fast Track
In addition to clinical trials in Korea, Cogthera is simultaneously pursuing German DiGA (Digital treatment and medical applications). DiGA is a fast-track system by German regulatory, BfArM, with an advantage of fast market entry and high reimbursement rate.
Solution 2
Digital Solutions for Learning Disorder
With Happymind, the developer of CAT, which has a high market share in Korea, we are rapidly growing by sharing development technology, know-how, and networks accumulated over the years. Happymind evaluates problems related to learning disorders such as attention deficit, poor reading skills and poor math skills, and provides solutions to them.
CATComprehensive Attention Test for children and adults
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROTOTYPE & TEST
DETAILED DESIGN
DATA COLLECTION & ANALYSIS
LAUNCH
NeuLearnApplication using neuroscience-based learning techniques to help memorize English words
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROTOTYPE & TEST
DETAILED DESIGN
DATA COLLECTION & ANALYSIS
LAUNCH
Dyscalculia Treatment ProgramProgram to treat those with mathematical and calculational difficulties
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROTOTYPE & TEST
DETAILED DESIGN
DATA COLLECTION & ANALYSIS
LAUNCH
sCATShort version of CAT for institutions
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROTOTYPE & TEST
DETAILED DESIGN
DATA COLLECTION & ANALYSIS
LAUNCH
CLTComprehensive Learning Test for early screening of dyslexia and dyscalculia in children and adolescents
DEFINE THE BRIEF
CONCEPT DEVELOPMENT
PROTOTYPE & TEST
DETAILED DESIGN
DATA COLLECTION & ANALYSIS
LAUNCH
3
Happymind Comprehensive attention Test helps objective assessment of attention
CAT
Happymind’s CAT (Comprehensive Attention Test) is a web-based test to comprehensively assess attention in children, adolescents, and adults.
It examines 5 different types of attention in 6 different tests: simple attention, selective attention, sustained attention, divided attention, and working memory. This allows you to assess whether you have attention level issues in each area.
Validated for reliability and accuracy through standardized studies with children and adolescents in Korea
Results can be interpreted in conjunction with intelligence tests, attention tests, and other academic achievement tests to increase the reliability of learning disorder diagnosis
4
Comprehensive Learning Test for early detection of dyslexia and dyscalculia in children and adolescents
CLT
Happymind’s CLT (Comprehensive Learning Test) is a web-based test for the early screening, diagnosis and measurement of improvement in children and adolescents at risk for dyslexia and dyscalculia.
It consists of small tests in reading and calculation.
The three founders of Emocog are all medical professionals. Our employees are also from leading companies around the world, united by a global mindset and a strong passion for what we do. In addition, we are partnering with our German team, with backgrounds and experience in various fields such as data technology and medical engineering, to enter the European and global markets.
Clinical & Regulatory
Co-CEO & Founder
Jun Young Lee, MD, PhD
Seoul National University, College of Medicine, PhD (Psychiatry)
Professor at Seoul National University College of Medicine (Psychiatry)
Korean Elderly Psychiatric Association
Director of Society for Cognitive Intervention
Co-CEO & Founder
Yoo Hun Noh, PhD
Chung-Ang University, College of Medicine, PhD
Former Professor at Chung-Ang University College of Medicine (Human Anatomy)
Consulting Member at KISTEP
Scientific Board & Founder
Jung Hae Youn, PhD
Paris 7, PhD
CEO of Cha Psychological Counselling Center
Professor at Cha University College of Medicine (Psychology)
Happymind CEO
Sunghee Kang, MA
New York University, Masters of Applied Psychology
Head of Happymind Lab
Medical Advisor
Yongjoon Yoo, MD
Seoul National University, College of Medicine (MD)
Psychiatrist
DTx Development
CTO Korea
Joonsang Jo
Seoul National University, Bachelor’s (Computer Science and Engineering)
